Freedom of information requests

The use of Biologic medicines in gastroenterology

Questions

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
·         Adalimumab - Humira
·         Adalimumab Biosimilar
·         Filgotinib
·         Golimumab
·         Infliximab - Remicade
·         Infliximab Biosimilar
·         Ozanimod
·         Tofacitinib
·         Upadacitinib
·         Ustekinumab
·         Vedolizumab
 
Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:
·         Adalimumab - Humira
·         Adalimumab Biosimilar
·         Golimumab
·         Infliximab - Remicade
·         Infliximab Biosimilar
·         Upadacitinib
·         Ustekinumab
·         Vedolizumab

Response

1. 

Drug	QE	HGS
Adalimumab - Humira	56	124
Adalimumab Biosimilar	0	131
Filgotinib	4	6
Golimumab	0	0
Infliximab - Remicade	9	0
Infliximab Biosimilar	0	248
Ozanimod	0	0
Tofacitinib	6	44
Upadacitinib	3	0
Ustekinumab	45	204
Vedolizumab	122	118

 

2. 

Drug	QE	HGS
Adalimumab - Humira	4	Not held
Adalimumab Biosimilar	3	Not held
Golimumab	0	Not held
Infliximab - Remicade	1	Not held
Infliximab Biosimilar	0	Not held
Upadacitinib	0	Not held
Ustekinumab	9	Not held
Vedolizumab	3	Not held